Application of fructus chebulae and active monomer thereof in preparation of products for inhibiting novel coronavirus and resisting Armike virus

• Main Authors: ZHANG MIN, ZHANG JUNHUA, WANG YUEFEI, WU HONGHUA, YU HUIJUAN, LIU LITING
• Format: Patent
• Language: Chinese; English
• Published: 29.03.2024
• Subjects: ACCESSORIES; AGRICULTURE; ANIMAL HUSBANDRY; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; FISHING; FORESTRY; HUMAN NECESSITIES; HUNTING; HYGIENE; MEDICAL OR VETERINARY SCIENCE; OUTERWEAR; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF; PROTECTIVE GARMENTS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS; TRAPPING; WEARING APPAREL

The invention belongs to the technical field of biology, and particularly relates to application of fructus chebulae and active monomers thereof in preparation of products for inhibiting novel coronavirus and resisting Armike virus. According to the application disclosed by the invention, research finds that active monomers of myrobalan tannic acid and punicalagin in myrobalan have very strong binding force on SARS-CoV-2 main protease and have a remarkable inhibition effect on the SARS-CoV-2 main protease, and finds that the active monomers of myrobalan tannic acid and punicalagin in myrobalan have a remarkable inhibition effect on Omicron BA.1 and BA.2 virus strains and are extremely low in half effect concentration for the first time. Therefore, the medicine terminalia fruit or the active monomers of the medicine terminalia fruit tannic acid and punicalagin, or the medicine terminalia fruit extract containing at least one of the two active monomers can be used for preparing a product for inhibiting the nove